




Somatuline[®] Depot (lanreotide) Injection

Directions for dosing

An EZ start with no prior short-acting therapy required¹



*Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline[®] Depot 60 mg.

Indication and safety information

Somatuline[®] Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline[®] Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients. Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline[®] Depot 60 mg.

Please see full Prescribing Information enclosed or visit www.somatulinedepot.com for additional important information.

EZ administration

**Simple, deep subcutaneous injection
with no reconstitution required¹**



- Let the Somatuline[®] Depot prefilled syringe come to room temperature 30 minutes prior to injection
- Remove the transparent plunger protector and twist off the rubber needle cap
- Inject Somatuline[®] Depot into the upper external part of the buttock
- Hold the skin around the injection site flat and insert the needle rapidly to its full length, keeping it perpendicular to the skin
- There is no need to rub or massage the injection site
- Remember to alternate between the left and right buttock each month

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline[®] Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.

Somatuline[®] Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline[®] Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection-site reaction, flatulence, arthralgia, and loose stools.

Please see full Prescribing Information enclosed or visit
www.somatulinedepot.com
for additional important information.



Reference: 1. Somatuline[®] Depot (lanreotide) Injection [prescribing information]. Paris, France: Beaufour Ipsen Pharma; 2007.

Somatuline[®] Depot is manufactured by Ipsen Pharma Biotech (Signes, France) for Beaufour Ipsen Pharma and distributed in the United States by Tercica, Inc.

www.somatulinedepot.com

©2007 Tercica, Inc. July 2008. DEP019US